Treating cancer cachexia to treat cancer

Skeletal Muscle

Volumn 1, Issue 1, 2011, Pages

  Lee, Se Jin ^a   Glass, David J ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 80054984740     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/2044-5040-1-3     Document Type: Note

References (31)

1. Glass DJ. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care 2010, 13:225-229. 10.1097/MCO.0b013e32833862df, 20397318.
2. Benny Klimek ME, Aydogdu T, Link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun 2010, 391:1548-1554. 10.1016/j.bbrc.2009.12.123, 20036643.
3. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543. 10.1016/j.cell.2010.07.011, 20723755.
4. Lee S-J. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 2004, 20:61-86. 10.1146/annurev.cellbio.20.012103.135836, 15473835.
5. McPherron AC, Lawler AM, Lee S-J. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 1997, 387:83-90. 10.1038/387083a0, 9139826.
6. Grobet L, Martin LJR, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein A, Dunner S, Ménissier F, Massabanda J, et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nature Genet 1997, 17:71-74. 10.1038/ng0997-71, 9288100.
7. Kambadur R, Sharma M, Smith TPL, Bass JJ. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 1997, 7:910-916.
8. McPherron AC, Lee S-J. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997, 94:12457-12461. 10.1073/pnas.94.23.12457, 24998, 9356471.
9. Schuelke M, Wagner KR, Stolz LE, Hübner C, Riebel T, Kömen W, Braun T, Tobin JF, Lee S-J. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004, 350:2682-2688. 10.1056/NEJMoa040933, 15215484.
10. Clop A, Marcq F, Takeda H, Pirottin D, Tordoir X, Bibe B, Bouix J, Caiment F, Elsen JM, Eychenne F, et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nature Genet 2006, 38:813-818. 10.1038/ng1810, 16751773.
11. Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG, Ostrander EA. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genetics 2007, 3:779-786.
12. Bogdanovich S, Krag TOB, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002, 420:418-421. 10.1038/nature01154, 12459784.
13. Whittemore LA, Song K, Li X, Aghajanian J, Davies MV, Girgenrath S, Hill JJ, Jalenak M, Kelley P, Knight A, et al. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 2003, 300:965-971. 10.1016/S0006-291X(02)02953-4, 12559968.
14. Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS, Lee S-J. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA 2003, 100:15842-15846. 10.1073/pnas.2534946100, 307655, 14671324.
15. Lee S-J, Reed A, Davies M, Girgenrath S, Goad M, Tomkinson K, Wright J, Barker C, Ehrmantraut G, Holmstrom J, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005, 102:18117-18122. 10.1073/pnas.0505996102, 1306793, 16330774.
16. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee S-J. Induction of cachexia in mice by systemically administered myostatin. Science 2002, 296:1486-1488. 10.1126/science.1069525, 12029139.
17. Lee S-J, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001, 98:9306-9311. 10.1073/pnas.151270098, 55416, 11459935.
18. Iezzi S, Di Padova M, Serra C, Caretti G, Simone C, Maklan E, Minetti G, Zhao P, Hoffman EP, Puri PL, Sartorelli V. Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell 2004, 6:673-684. 10.1016/S1534-5807(04)00107-8, 15130492.
19. Minetti GC, Colussi C, Adami R, Serra C, Mozetta C, Parente V, Fortuni S, Straino S, Sampaolesi M, Di Padova M, et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 2006, 12:1147-1150. 10.1038/nm1479, 16980968.
20. Moustakas A, Heldin CH. The regulation of TGFβ signal transduction. Development 2009, 136:3699-3714. 10.1242/dev.030338, 19855013.
21. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009, 296:C1258-C1270. 10.1152/ajpcell.00105.2009, 19357233.
22. Gilson H, Schakman O, Kalista S, Lause P, Tsuchida K, Thissen JP. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. Am J Physiol Endocrinol Metab 2009, 297:E157-E164. 10.1152/ajpendo.00193.2009, 19435857.
23. Matzuk MM, Finegold MJ, Su J-GJ, Hsueh AJW, Bradley A. α-Inhibin is a tumor-suppressor gene with gonadal specificity in mice. Nature 1992, 360:313-319. 10.1038/360313a0, 1448148.
24. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 1994, 91:8817-8821. 10.1073/pnas.91.19.8817, 44697, 8090730.
25. Li Q, Kumar R, Underwood K, O'Connor AE, Loveland KL, Seehra JS, Matzuk MM. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. Mol Hum Reprod 2007, 13:675-683. 10.1093/molehr/gam055, 17704537.
26. Sharma M, Kambadur R, Matthews KG, Somers WG, Devlin GP, Conaglen JV, Fowke PJ, Bass JJ. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 1999, 180:1-9. 10.1002/(SICI)1097-4652(199907)180:1<1::AID-JCP1>3.0.CO;2-V, 10362012.
27. Shyu KG, Lu MJ, Wang BW, Sun HY, Chang H. Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure. Eur J Clin Invest 2006, 36:713-719. 10.1111/j.1365-2362.2006.01718.x, 16968467.
28. Lenk K, Schur R, Linke A, Erbs S, Matsumoto Y, Adams V, Schuler G. Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur J Heart Fail 2009, 11:342-348. 10.1093/eurjhf/hfp020, 19218333.
29. George I, Bish LT, Kamalakkannan G, Petrilli CM, Oz MC, Naka Y, Sweeney HL, Maybaum S. Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail 2010, 12:444-453. 10.1093/eurjhf/hfq039, 20348550.
30. Heineke J, Auger-Messier M, Xu J, Sargent M, York A, Welle S, Molkentin JD. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 2010, 121:419-425. 10.1161/CIRCULATIONAHA.109.882068, 20065166.
31. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997, 349:1050-1053. 10.1016/S0140-6736(96)07015-8, 9107242.